The FDA's 15-day acceptance/refusal review window is the immediate catalyst — a refusal to accept would be negative, while acceptance triggers a 70-day feedback period. Monitor for the FDA's initial decision within the next two weeks, which will set the tone for the clearance timeline.
Price Chart
Executive Summary
BioCardia announced it has completed a revised De Novo pre-submission to the FDA's CDRH for its Helix Catheter, a device for therapeutic and diagnostic agent delivery to the heart. The FDA has not raised safety or performance concerns in prior meetings and targets initial acceptance/refusal review within 15 calendar days, with written feedback or a meeting within 70 days. Clearance would be a transformative milestone for this early-stage biotech, potentially enabling partnerships with developers of cell, gene, and protein therapeutics.
Key Facts
- BioCardia completed a revised De Novo pre-submission to FDA CDRH for the Helix Catheter.
- FDA targets initial acceptance/refusal review within 15 calendar days and written feedback or meeting within 70 calendar days.
- FDA previously agreed there are two pathways for Helix marketing clearance and raised no concerns on safety data, device performance, or agent compatibility.
- Helix has clinical data from 15 trials with nearly 500 patients.
- Clearance would make Helix the first device of its kind cleared by FDA, potentially creating a non-inferiority benchmark for follow-on catheters.
- BioCardia is an early-stage biotech with no approved commercial product; Helix clearance would be a first commercial asset.
Financial Impact
Not stated in the press release; no revenue or financial figures provided.
Risk Factors
- FDA may refuse to accept the De Novo submission, delaying or ending the clearance pathway.
- BioCardia's liquidity position and ability to fund operations through the regulatory process is a stated risk factor.
- Even if accepted, FDA feedback could require additional data or changes, extending the timeline.
- The company has no approved products and limited revenue, making it dependent on regulatory success and financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers